CN111699189B - 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 - Google Patents
可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 Download PDFInfo
- Publication number
- CN111699189B CN111699189B CN201880088219.8A CN201880088219A CN111699189B CN 111699189 B CN111699189 B CN 111699189B CN 201880088219 A CN201880088219 A CN 201880088219A CN 111699189 B CN111699189 B CN 111699189B
- Authority
- CN
- China
- Prior art keywords
- phenyl
- methyl
- pyridin
- dihydro
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762595133P | 2017-12-06 | 2017-12-06 | |
| US62/595,133 | 2017-12-06 | ||
| PCT/US2018/064316 WO2019113359A1 (en) | 2017-12-06 | 2018-12-06 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111699189A CN111699189A (zh) | 2020-09-22 |
| CN111699189B true CN111699189B (zh) | 2025-02-18 |
Family
ID=64744985
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880088219.8A Active CN111699189B (zh) | 2017-12-06 | 2018-12-06 | 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11339172B2 (https=) |
| EP (1) | EP3720858B1 (https=) |
| JP (1) | JP7357617B2 (https=) |
| CN (1) | CN111699189B (https=) |
| AR (1) | AR114156A1 (https=) |
| ES (1) | ES2953576T3 (https=) |
| MA (1) | MA51015A (https=) |
| TW (1) | TWI822713B (https=) |
| WO (1) | WO2019113359A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA44037B1 (fr) | 2016-06-06 | 2020-03-31 | Arena Pharm Inc | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| CN111699189B (zh) * | 2017-12-06 | 2025-02-18 | 艾尼纳制药公司 | 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| US20250127773A1 (en) * | 2021-08-09 | 2025-04-24 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure |
| JP2024532227A (ja) | 2021-08-26 | 2024-09-05 | アリーナ ファーマシューティカルズ， インコーポレイテッド | 腎嚢胞性疾患および心腎症候群の処置または予防のためのベータ３アドレナリン作動性受容体のモジュレーター |
| US20240409548A1 (en) | 2021-10-06 | 2024-12-12 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214002A1 (en) * | 2016-06-06 | 2017-12-14 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5451677A (en) * | 1993-02-09 | 1995-09-19 | Merck & Co., Inc. | Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity |
| FR2755439B1 (fr) | 1996-11-05 | 1998-12-24 | Virbac Sa | Derives aryloxypropanolamines, leur procede de preparation et leurs applications |
| JP4782342B2 (ja) | 1999-12-17 | 2011-09-28 | サノフィ−アベンティス | フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物 |
| CZ20031012A3 (en) * | 2000-10-20 | 2004-04-14 | Pfizer Products Inc. | Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| US20080255134A1 (en) | 2004-11-30 | 2008-10-16 | Artesian Therapeutics, Inc. | Cardiotonic Compounds With Inhibitory Activity Against Beta-Adrenergic Receptors And Phosphodiesterase |
| PT3206678T (pt) | 2014-10-14 | 2020-03-23 | Sculpt B V | Escultura corporal |
| CN111699189B (zh) | 2017-12-06 | 2025-02-18 | 艾尼纳制药公司 | 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 |
-
2018
- 2018-12-06 CN CN201880088219.8A patent/CN111699189B/zh active Active
- 2018-12-06 WO PCT/US2018/064316 patent/WO2019113359A1/en not_active Ceased
- 2018-12-06 TW TW107143855A patent/TWI822713B/zh active
- 2018-12-06 MA MA051015A patent/MA51015A/fr unknown
- 2018-12-06 EP EP18822236.8A patent/EP3720858B1/en active Active
- 2018-12-06 JP JP2020530969A patent/JP7357617B2/ja active Active
- 2018-12-06 ES ES18822236T patent/ES2953576T3/es active Active
- 2018-12-06 US US16/769,507 patent/US11339172B2/en active Active
- 2018-12-06 AR ARP180103577A patent/AR114156A1/es unknown
-
2022
- 2022-04-22 US US17/726,807 patent/US11987588B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214002A1 (en) * | 2016-06-06 | 2017-12-14 | Arena Pharmaceuticals, Inc. | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3720858C0 (en) | 2023-06-07 |
| US11987588B2 (en) | 2024-05-21 |
| CN111699189A (zh) | 2020-09-22 |
| ES2953576T3 (es) | 2023-11-14 |
| MA51015A (fr) | 2021-04-21 |
| US11339172B2 (en) | 2022-05-24 |
| JP2021505598A (ja) | 2021-02-18 |
| AR114156A1 (es) | 2020-07-29 |
| US20200385395A1 (en) | 2020-12-10 |
| WO2019113359A1 (en) | 2019-06-13 |
| TW201925206A (zh) | 2019-07-01 |
| EP3720858A1 (en) | 2020-10-14 |
| US20220396579A1 (en) | 2022-12-15 |
| JP7357617B2 (ja) | 2023-10-06 |
| EP3720858B1 (en) | 2023-06-07 |
| TWI822713B (zh) | 2023-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111699189B (zh) | 可用于治疗或预防与其相关的心力衰竭和障碍的β-3肾上腺素能受体的调节剂 | |
| AU2021206809B2 (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| AU2013312931B2 (en) | Alkoxy pyrazoles as soluble guanylate cyclase activators | |
| CN112638917A (zh) | 作为激酶抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 | |
| JP2022502484A (ja) | キナーゼ阻害活性を有する芳香族複素環式化合物 | |
| HK40039344A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| HK40039344B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto | |
| WO2026026956A1 (zh) | Tacc抑制剂化合物、药物组合物及其制备方法和应用 | |
| HK40046602A (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| HK40004811A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| HK40004811B (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | |
| HK40006318A (en) | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |